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Purpose: The risk of invasive fungal infection is greater for allogeneic hematopoi-
etic stem cell transplantation (HSCT) than for autologous transplantation. There-
fore, many transplantation centers use antifungal prophylaxis for allogeneic 
HSCT, however, there exists no standard guidelines or consensus regarding autol-
ogous HSCT. Materials and Methods: A prospective double-blind randomized 
study was conducted in autologous HSCT recipients who were divided into pro-
phylaxis and empirical treatment groups, and we investigated the efficacy of itra-
conazole prophylaxis in pediatric autologous HSCT. Results: Total 87 autologous 
HSCT episodes in 55 children with high-risk solid tumors were studied. No inva-
sive fungal infections occurred in either group. However, patients in the prophy-
laxis group had a significantly shorter duration of fever (p < 0.05) and received an-
tibacterial treatment of shorter duration (p < 0.05) with fewer numbers of 
antibiotics (p < 0.05 for the use of second line antibiotics) than those in the empiri-
cal group. No significant additional adverse events were found with itraconazole 
prophylaxis. Conclusion: Although beneficial effects such as a shorter duration of 
fever and reduced need for antibiotic use were observed in the prophylaxis group, 
the results were not sufficient to draw a definite recommendation about the routine 
use of antifungal prophylaxis in pediatric autologous HSCT recipients with high-
risk solid tumors (Trial registration: NCT00336531).
Key Words:    Itraconazole, autologous transplantation, antifungal prophylaxis, sol-
id tumor
INTRODUCTION
High-dose chemotherapy (HDCT) and autologous hematopoietic stem cell trans-
plantation (HSCT) are currently the modalities of choice for the treatment of chil-
dren with high-risk solid tumors that respond poorly to conventional chemothera-
py. While HDCT and autologous HSCT have improved the survival of these 
patients, significant treatment-related morbidity and mortality remain, for which 
infectious complications play a major role.  Yae-Jean Kim, et al.
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tained from the parents of each patient.
Use of itraconazole and antibacterial agents for 
neutropenic fever
Patients were randomized in a double-blinded manner into 
either a prophylaxis or an empirical treatment group, and 
were prospectively evaluated for the safety and efficacy of 
itraconazole prophylaxis. In the prophylaxis group, itracon-
azole was given intravenously (2.5 mg/kg/dose, twice daily 
for the first two days followed by 2.5 mg/kg/dose once dai-
ly for the duration of treatment) after the absolute neutro-
phil count (ANC) fell below 0.5 × 109/L after initiation of 
HDCT, even in the absence of a high fever. In the empirical 
treatment group, a placebo was given once the ANC fell 
below 0.5 × 109/L after the initiation of HDCT, and itracon-
azole was started only when a high fever persisted for more 
than three days or if fever recurred despite the use of first-
line antibiotics for more than three days. A placebo visibly 
identical to normal saline was provided by the pharmacy. 
Itraconazole level was not measured because the procedure 
was not available at our institution. 
Cefepime was used as the first-line antibacterial agent, and 
teicoplanin and amikacin were added as second-line agents if 
fever persisted for three days on cefepime, or if a fever re-
curred despite more than three days of cefepime treatment. 
The antibiotic regimen was changed to imipenem and teico-
planin as third-line agents for patients who had persistent 
neutropenic fever for an additional three days or for recurrent 
fever after treatment with three antibiotics for more than 
three days. All antibiotics including itraconazole were dis-
continued after three consecutive days of no significant fever 
(< 37.5°C), no evidence of documented or clinically suspect-
ed infection, and an ANC exceeding 0.5 × 109/L. For micro-
biologically documented infections, the antibiotic regimen 
was altered as needed. 
In all patients, chest X-rays and cultures from blood, urine, 
and stool specimens were performed on first fever episodes 
and before changing antibiotics. In some patients with pro-
longed fever for more than 7-10 days, additional studies 
such as chest or abdominal CT or ultrasound examination 
were performed. Tests for serum Aspergillus antigen were 
performed in certain patients. 
Assessment of efficacy 
Patients were assessed for the development of invasive fun-
gal infections until 30 days post-transplantation or the time 
of discharge. Clinical parameters such as the total duration 
Invasive fungal infection is one of the most important 
treatment-related complications of allogeneic HSCT recipi-
ents. Various prophylactic antifungal agents are used in 
transplantation centers according to standard guidelines for 
allogeneic HSCT.1-4 However, no standard guidelines or 
consensus exists on the use of antifungal prophylaxis for 
autologous HSCT recipients, since they are generally con-
sidered to have a more rapid hematological recovery and 
require less severe immune suppression than allogeneic 
HSCT recipients. In general, routine antifungal prophylaxis 
has not been recommended for autologous HSCT recipi-
ents. However, studies have recommended administering 
antifungal prophylaxis to subpopulations of autologous re-
cipients with underlying hematological malignancies such 
as lymphoma or leukemia, or those who have or will have 
prolonged neutropenia and mucosal damage from intense 
conditioning regimens or graft manipulation.5 Therefore, 
even in the autologous HSCT setting, patients with certain 
conditioning regimens with a high rate of mucositis might 
be susceptible to invasive fungal infection and require anti-
fungal prophylaxis during the early post-HSCT period, un-
til neutropenia and mucositis are resolved.
Itraconazole is an antifungal agent that belongs to the 
azole class and has been used as a first-line antifungal agent 
for the management of neutropenic fever in immunocom-
promised patients.6,7 However, the efficacy of prophylactic 
itraconazole has not yet been established for pediatric autolo-
gous HSCT recipients. In the present double-blind random-
ized clinical trial, the efficacy of prophylactically-adminis-
tered itraconazole was prospectively evaluated in pediatric 
autologous HSCT recipients with high-risk solid tumors. 
The efficacy and safety of itraconazole prophylaxis were 
compared to those of empirical treatment. 
MATERIALS AND METHODS
Patients
From April 2006 to March 2008, fifty-five patients with 
high-risk solid tumors at the Pediatric Stem Cell Transplan-
tation Unit of Samsung Medical Center had 90 autologous 
HSCT episodes that were eligible for this study. The high-
risk solid tumors included high-risk neuroblastoma, high-
risk embryonal brain tumor, bilateral advanced retinoblas-
toma, and relapsed solid tumors. The Samsung Medical 
Center Institutional Review Board approved the protocols 
used for this study, and written informed consent was ob-Itraconazole Prophylaxis for Auto HSCT
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to severe cyclophosphamide-related myocarditis. In the pro-
phylaxis group, one patient who had received itraconazole 
for four days developed asphyxia and a severe hypoxic inju-
ry, and later died of multiorgan failure. These deaths were 
not considered to be associated with itraconazole treatment. 
Therefore, 85 episodes (42 in the prophylactic group and 43 
in the empirical group) were analyzed. The two groups had 
similar clinical characteristics, and the clinical parameters 
for the risk of developing invasive fungal infection were 
comparable between the two groups (Table 1). 
Efficacy analysis
No cases of proven, probable, or possible invasive fungal 
infection occurred in either group. However, the duration of 
fever above 38°C was significantly shorter in the prophy-
laxis group than in the empirical group (4.7 ± 2.4 days vs. 
6.5 ± 3.5 days, p = 0.007, Fig. 1A). In addition, the number 
of patients who had fever for more than seven days, which 
were the duration of antibiotic use, and the number of pa-
tients who needed additional second-line antibiotic treat-
ment were significantly lower in the prophylaxis group than 
in the empirical groups (Table 2). No significant differences 
in the development of documented viral or bacterial infec-
tions were observed between the two groups. 
Multivariate analysis showed that prophylactic use of 
itraconazole was associated with shorter duration of fever, 
and that treatment with a thiotepa-containing regimen was 
associated with longer duration of fever (Table 3). Thiotepa 
is a well-known chemotherapeutic agent that causes severe 
mucositis and thus fever. A subgroup analysis of patients 
who were treated with a thiotepa-containing regimen showed 
that the prophylaxis group still had a shorter duration of fe-
ver (Fig. 1B). Another subgroup analysis of patients who 
did not have severe diarrhea showed that the prophylaxis 
group also had a shorter duration of fever (Fig. 1C).
Safety analysis
High grade toxicities (grade ≥ 3), including stomatitis, diar-
rhea, increased liver enzymes, hypokalemia, and hypophos-
phatemia, developed in more than one-third of the patients. 
However, no difference was observed in the development 
of serious adverse events between the prophylaxis group 
and the empirical treatment group, even though the prophy-
laxis group received itraconazole for a longer duration (13.9 
± 2.8 days vs. 8.9 ± 3.8 days, p < 0.001)(Table 4). In all but 
two HSCT episodes, patients received cefepime for neutro-
penic fever with no episodes of neurotoxicity. 
of fever and duration of antibiotic treatment were also eval-
uated over this period. Other parameters that could have in-
fluenced the development of infectious complications were 
also compared, including age, underlying disease, tumor re-
currence, time from diagnosis to transplantation, type of 
HDCT regimen, number of transplantations (first vs. sec-
ond in tandem transplantation), infused stem cell number, 
time to reach an ANC of 0.5 × 109/L, and duration of severe 
neutropenia (ANC < 0.5 × 109/L). 
Assessment of safety
Adverse events were recorded until 30 days post-transplan-
tation or the time of discharge. Data from renal and liver 
function tests were also analyzed. Events were classified 
according to the Common Toxicity Criteria grading system 
of the National Cancer Institute.8 
Assessment of cost-effectiveness 
Costs between the two groups were compared in terms of 
duration of hospitalization, cost of total treatment during 
the transplantation period, and cost of antimicrobial agents. 
Statistical analyses
The Chi-square test was performed to compare the frequency 
of factors that were suspected to increase the risk of fungal 
infections. The Mann-Whitney U test was performed to 
compare infused stem cell numbers and hematological re-
covery between the two groups. The Student’s t-test was per-
formed to compare the total duration of fever and antibiotic 
treatment between the two groups, and to compare the dura-
tion of hospitalization and the cost of treatment. Differences 
in the frequencies of various toxicities between the two 
groups were analyzed using a Chi-square test. Multivariate 
analysis was also performed using linear regression analysis 
to examine the factors associated with duration of fever. 
RESULTS
Patient characteristics 
A total of 90 transplantation episodes in 55 pediatric pa-
tients met the criteria for this study. Three patients were ex-
cluded because of complications that occurred before the 
initiation of itraconazole or placebo treatment. In total, 87 
transplantation episodes (43 in the prophylactic group and 
44 in the empirical group) were included. In the empirical 
treatment group, one patient receiving the placebo died due Yae-Jean Kim, et al.
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Table 1. Patient Characteristics 
Prophylactic (n = 42) Empirical (n = 43) p value
Age at HDCT (months)    49 (15 - 300)*    46 (17 -3 02)  0.613
Underlying disease  0.667
    Neuroblastoma    16 (38.1%)    18 (41.9%)
    Brain tumor    17 (40.5%)    19 (44.2%)
    Retinoblastoma      4 (9.5%)      4 (9.3%)
    Wilms tumor      2 (4.8%)      2 (4.7%)
    Osteosarcoma      2 (4.8%)      0 (0%)
    Primitive neuroectodermal tumor      1 (2.4%)      0 (0%)
    Newly diagnosed    35 (83.3%)    36 (83.7%) 0.962
    Relapsed      7 (16.7%)      7 (16.3%)
Time from diagnosis to HDCT (months)    10 (6 - 36)    10 (6 - 56) 0.979
HDCT regimen 0.208
    CEC    12 (28.6%)    10 (23.3%)
    TM/TM-TBI      7 (16.7%)    11 (25.6%)
    CTE       8 (19.0%)    14 (32.6%)
    CM    13 (31.0%)      8 (18.6%)
    ICE      2 (4.8%)      0 (0%)
First HDCT    20 (47.6%)    23 (53.5%) 0.588
Second HDCT    22 (52.4%)    20 (46.5%)
Infused cells
    CD34
+ cells (× 10
6/kg)   6.8 (1.0 - 220.2)   6.1 (0.6 - 131.1) 0.571
    CFU-GM (× 10
5/kg) 14.3 (0.1 - 688.0) 17.6 (0.3 - 381.0) 0.702
Hematologic recovery
    Time to ANC > 0.5 × 10
9/l (days)
†    10 (8 - 15)      9 (7 - 16) 0.378
    Duration of ANC < 0.5 × 10
9/l (days)    11 (6 - 22)    10 (5 - 18) 0.495
    Time to PLT 20 × 10
9/l (days)
† 19.5 (13 - 167)    19 (13 - 59) 0.757
HDCT, high-dose chemotherapy; ANC, absolute neutrophil count.
CEC, carboplatin 1,950 mg/m
2 + etoposide + 1,950 mg/m
2 + cyclophosphamide 5,400 mg/m
2; TM, thiotepa 900 mg/m
2 + melphalan 120 
mg/m
2; TM-TBI, thiotepa 600 mg/m
2 + melphalan 120 mg/m
2 + total body irradiation 9.99 Gy; CTE, carboplatin 1,500 mg/m
2 + thiotepa 
900 mg/m
2 + etoposide 750 mg/m
2; CM, cyclophosphamide 6,000 mg/m
2 + melphalan 180 mg/m
2; ICE, ifosfamide 16,000 mg/m
2 + car-
boplatin 1,800 mg/m
2 + etoposide 1,500 mg/m
2. 
*Median (range).
†Time required to reach an ANC 0.5 × 10
9/l and a platelet count of 20 × 10
9/l with no transfusions in the previous seven days.
Fig. 1. Duration of fever was shorter in the prophylaxis group than in the empirical treatment group. (A) Duration of fever in all patients. (B) 
Duration of fever in patients who were treated with a thiotepa-containing regimen. (C) Duration of fever in patients who did not have se-
vere diarrhea.
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treatment during hospitalization and the cost of total antimi-
crobial agents were lower in the prophylaxis group than in 
the empirical group, but these findings were also not signifi-
cant (Table 2).
Cost-effectiveness analysis 
The duration of hospitalization for transplantation was short-
er in the prophylaxis group than in the empirical group; how-
ever, this result was not significant. Similarly, the cost of total 
Table 2. Efficacy and Cost-Effectiveness of Itraconazole Prophylaxis
Prophylactic (n = 42) Empirical (n = 43) p value
Proven or probable invasive fungal infection 0 (0%) 0 (0%) 1.000
Other infection, total   6 (14.3%) 11 (25.6%) 0.279
    Bacterial, blood 4 (9.5%)   7 (16.3%) 0.520
    Bacterial, urine 0 (0%) 4 (9.3%) 0.116
    Viral 2 (4.8%) 0 (0%) 0.241
Duration of high fever 
    Days of ≥ 38.0°C   4.7 ± 2.4   6.5 ± 3.5 0.007
    Days of ≥ 38.3°C   2.7 ± 2.0   4.1 ± 2.7 0.010
    Days of ≥ 38.5°C   2.0 ± 2.0   3.1 ± 2.4 0.017
No. of patients with high fever 
(≥ 38.0°C) for ≥ seven days
  8 (19.0%) 19 (44.2%) 0.013
Application of first-line antibiotics 40 (95.2%) 43 (100%) 0.962
Application of second-line antibiotics 32 (76.2%) 41 (95.3%) 0.011
Application of third-line antibiotics 16 (38.1%) 24 (55.8%) 0.102
Duration of antibacterial agents (days) 11.5 ± 4.1 13.4 ± 3.3 0.024
Duration of itraconazole (days) 13.9 ± 2.8   8.9 ± 3.8 < 0.001
Duration of hospitalization (days) 17.7 ± 3.4   19.7 ± 10.2 0.247
Cost of total treatment ($) 16,010 ± 3,602 18,985 ± 9,458 0.059
Cost of total antimicrobial agents ($)   759 ± 427   969 ± 804 0.137
Table 3. Multivariate Analysis for Factors Affecting Duration of High Fever (≥ 38.0°C)
Risk factors t-score
95% confidence interval
p value
Lower Upper
Neuroblastoma - 0.038 - 1.982   1.908 0.970
Relapsed tumor - 1.120 - 2.991   0.838 0.266
Age < 4 yrs   0.392 - 1.078   1.605 0.696
Thiotepa-containing regimen   2.373   0.270   3.096 0.020
Application of total body irradiation   0.225 - 2.577   3.233 0.823
Second HDCT - 1.096 - 2.129   0.618 0.277
Infused CD34 + cells < 5 × 10
6/kg   0.093 - 1.673   1.836 0.926
Prophylactic use of itraconazole - 2.069 - 2.692 - 0.051 0.042
HDCT, high-dose chemotherapy.
Table 4. Grade 3 and 4 Toxicities 
Prophylactic (n = 42) Empirical (n = 43) p value
Vomiting 13 (31.0)  8 (18.6) 0.187
Stomatitis 14 (33.3) 17 (39.5) 0.553
Diarrhea (≥ 10 times/day) 22 (52.4) 23 (53.5) 0.919
Hyperbilirubinemia 1 (2.4) 1 (2.3) 0.987
Elevation of liver enzymes 19 (45.2) 19 (44.2) 0.922
Hepatic veno-occlusive disease   6 (14.3) 12 (27.9) 0.124
Azotemia 1 (2.4) 1 (2.3) 0.987
Hyponatremia   5 (11.9) 4 (9.3) 0.697
Hypokalemia 28 (66.7) 23 (53.5) 0.215
Hypophosphatemia 15 (35.7) 16 (37.2) 0.886Yae-Jean Kim, et al.
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However, the duration of fever was significantly shorter in 
the prophylaxis group compared to the empirical group, 
while no differences were observed between the two groups 
in the frequency of factors that might increase the chance of 
infection. In addition, patients in the itraconazole prophy-
laxis group required a shorter duration of antibacterial treat-
ment, and fewer prophylaxis patients needed second- and 
third-line antibiotic regimens. These findings suggest that 
undiagnosed subclinical fungal infections could have oc-
curred in many of our patients, and that the antifungal agent 
was beneficial for the patients in the prophylaxis group. In 
this way, the antifungal prophylaxis may have influenced the 
requirement for second- or third-line antibacterial agents. 
Invasive fungal infections in autologous HSCT recipients 
occur most frequently during the pre-engraftment period.31 
During pre-engraftment neutropenia, mucositis and the 
presence of indwelling central venous catheters are impor-
tant risk factors. Multivariate analysis indicated that treat-
ment with thiotepa-containing regimens and the prophylac-
tic use of itraconazole were independent factors associated 
with fever duration. Since mucositis facilitates the develop-
ment of fungal infection, mainly from Candida species, via 
damaged mucosal barriers, we expected that the benefit 
from antifungal prophylaxis would be greater in patients 
with severe mucositis than in patients without mucositis. A 
subgroup analysis of patients who received thiotepa and de-
veloped severe mucositis showed that the prophylaxis group 
had a shorter duration of fever than did the empirical treat-
ment group. However, in patients without severe diarrhea, 
the prophylaxis group also had a shorter duration of fever. 
These findings suggest that antifungal prophylaxis could 
have contributed to a reduced duration of fever regardless 
of the severity of the gross mucositis. 
A meta-analysis of randomized-controlled trials compar-
ing fluconazole and itraconazole for antifungal prophylaxis 
in patients with neutropenia and hematological malignan-
cies suggested that, even though itraconazole might be 
more effective than fluconazole for preventing fungal infec-
tions, its association with more adverse effects may limit its 
use.7 In contrast, a study that compared posaconazole and 
fluconazole or itraconazole prophyalxis in patients with 
neutropenia showed that itaconazole did not have a signifi-
cantly increased frequency of serious adverse events com-
pared to fluconazole or posaconazole.32 In the present study, 
no difference in serious adverse events was observed be-
tween the prophylaxis group and the empirical treatment 
group, even though the prophylaxis group received itracon-
DISCUSSION
The risk of invasive fungal infection after HSCT is greater 
in allogeneic HSCT recipients than in autologous HSCT re-
cipients.9-19 The incidence of invasive fungal infection in 
pediatric allogeneic HSCT recipients is reported to be 1.3-
13% for Candida infection and 3-14% for mold infection, 
while, the incidence is 5-6% for Candida infection and 0.3-
3% mold infection in autologous HSCT recipients.17,20-25 
Nationwide data of 152,231 immunocompromised children 
in the United States, including 822 autologous HSCT recip-
ients, show that 0.3% of autologous HSCT recipients had 
invasive aspergillosis.17 Therefore, although less frequent 
than in allogeneic patients, serious invasive fungal infec-
tions can still occur in autologous HSCT recipients.13,19,26-29
Very limited data are available on the effects of antifungal 
prophylaxis in autologous HSCT recipients, particularly in 
pediatric recipients with high-risk sold tumors. In a meta-
analysis of antifungal prophylaxis reported by Robenshtok, 
et al.30 antifungal prophylaxis reduced all-cause mortality, 
fungal-related mortality, and invasive fungal infections in al-
logeneic recipients. For autologous HSCT, effect estimates 
of antifungal prophylaxis [RR 0.27, 95% confidence interval 
(CI) 0.08-0.95 for all-cause mortality; RR 0.28, 95% CI 
0.06-1.28 fungal-related mortality; RR 0.36, 95% CI 0.13-
1.01 for invasive fungal infection] were similar to those for 
allogeneic HSCT recipients (RR 0.62, 95% CI 0.45-0.85 for 
all-cause mortality; RR 0.52, 95% CI 0.27-0.99 for fungal-
related mortality; RR 0.33, 95% CI 0.18-0.63 for invasive 
fungal infection]. However, in this study, the samples lacked 
the power to reach significance, so that the data were insuffi-
cient to determine whether antifungal prophylaxis should be 
recommended for patients with solid tumors undergoing au-
tologous HSCT. Therefore, the topic of whether antifungal 
prophylaxis should be recommended for autologous HSCT 
recipients is still under debate. While many transplantation 
centers have used antifungal prophylaxis for allogeneic 
HSCT recipients, no standard guidelines or consensus about 
the use of antifungal prophylaxis in autologous HSCT recip-
ients have been established. In this context, we investigated 
the efficacy of prophylactic itraconazole by comparing with 
that of empirical treatment in pediatric autologous HSCT re-
cipients with high-risk solid tumors. 
Since no case of fungal infection occurred in either study 
group, we could not determine the efficacy of antifungal 
prophylaxis for the prevention of invasive fungal infection. Itraconazole Prophylaxis for Auto HSCT
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costs in the prophylaxis group than for the empirical treat-
ment group. The issue of cost-effectiveness of antifungal 
prophylaxis requires further attention. 
The above findings suggest that some autologous HSCT 
recipients might benefit from antifungal prophylaxis with-
out increased toxicity, although the incidence of invasive 
fungal infection is low in autologous HSCT recipients. How-
ever, patients with prophylaxis received a longer duration 
of antifungal treatment than those in the empirical treat-
ment group, so that the benefits from prophylaxis must be 
weighed with caution against a potential increase in the risk 
of drug toxicity, increased cost, and selection for resistant 
and rare fungal pathogens. The above factors are associated 
with longer use of antifungal agents, although they were 
not observed in this study. 
In summary, this study was the first prospective double-
blinded randomized trial to examine the efficacy of prophy-
lactic antifungal use in pediatric autologous HSCT recipients 
with high-risk solid tumors. Although some beneficial ef-
fects, including a shorter duration of fever and reduced need 
for antibiotic use were observed for the prophylaxis group, 
this study could not definitely conclude if antifungal prophy-
laxis should be routinely recommended for pediatric autolo-
gous HSCT recipients with high-risk solid tumors. Further 
investigation with a larger cohort of patents is needed.
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